Articles tagged with: Pomalidomide

News»

[ by and | Oct 2, 2013 7:21 pm | One Comment ]
Pomalyst-Cyclophosphamide-Prednisone Combination Effective And Safe In Relapsed Multiple Myeloma

Results from a recent Italian Phase 1/2 clinical trial indicate that the com­bi­na­tion of Pomalyst, cyclo­phos­pha­mide, and prednisone is effective and safe in re­lapsed and re­frac­to­ry multiple myeloma patients.

Overall, 51 percent of patients in the trial responded to the treat­ment, and the me­di­an pro­gres­sion-free survival time was 10.4 months. The me­di­an overall survival had not been reached yet; however, 69 percent of patients were alive one year after starting treat­ment.

The study participants had previously been treated with a me­di­an of three prior therapies, and all had re­ceived prior …

Read the full story »

News»

[ by | Sep 18, 2013 3:02 pm | 3 Comments ]
Researchers Publish Final Results Of Pomalyst Trial That Led To Approval In Europe

Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with Revlimid and Velcade.

Specifically, the results show that patients receiving Pomalyst (pomalidomide, Imnovid) in combination with low-dose dexamethasone (Decadron) had higher response rates and longer progression-free and overall survival than patients who received high-dose dexamethasone alone.

High-dose dexamethasone was chosen as the comparator in this study because, according to the study investigators, it was a common rescue …

Read the full story »

News»

[ by and | Sep 4, 2013 9:21 pm | 2 Comments ]
Kyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?

A new retrospective study provides insight into the benefit the new mye­lo­ma drugs Kyprolis and Pomalyst may provide to patients who are re­sis­tant to, or cannot tolerate, both Velcade and Revlimid.

The study’s results highlight how challenging it can be to find an effective treat­ment for patients who are “dual refractory” (resistant to both Velcade and Rev­li­mid).

Patients in the study who received either Kyprolis (carfilzomib) or Poma­lyst (poma­lido­mide, Imnovid) after becoming dual refractory had longer overall survival than those who were not treated with the new …

Read the full story »

News»

[ by | Aug 9, 2013 3:42 pm | 4 Comments ]
Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma

The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma.  The European brand name for the drug is expected to be “Imnovid,” although final regu­la­tory approval of that name is still pending.

In the United States, pomalidomide is marketed under the brand name Poma­lyst.  It was approved earlier this year by the U.S. Food and Drug Ad­min­is­tra­tion (FDA) as a new treatment for myeloma.

The EC approved Imnovid for use in combination with dexamethasone (Decadron) in …

Read the full story »

News»

[ by | Updated: Jun 19, 2013 11:10 pm | Comments Off ]
The European Hematology Association’s Annual Congress Starts Today: A Look At The Key Myeloma-Related Presentations (EHA 2013)

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related dis­eases, in­clud­ing multiple myeloma.

The EHA …

Read the full story »